Infliximab cost-effectiveness/safety? - Suppr | 超能文献

Infliximab cost-effectiveness/safety?

作者信息

Rothschild B M

出版信息

Rheumatology (Oxford). 2003 Dec;42(12):1572-3; author reply 1573-4. doi: 10.1093/rheumatology/keg409.

DOI:10.1093/rheumatology/keg409

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Infliximab cost-effectiveness/safety?

Rheumatology (Oxford). 2003 Dec;42(12):1572-3; author reply 1573-4. doi: 10.1093/rheumatology/keg409.

2

Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result.

Rheumatology (Oxford). 2003 Dec;42(12):1574-5; author reply 1573-4. doi: 10.1093/rheumatology/keg456.

3

Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.英夫利昔单抗治疗类风湿关节炎的药物经济学评价——对635例患者进行为期两年监测的法国前瞻性队列研究

Rheumatology (Oxford). 2009 Oct;48(10):1236-41. doi: 10.1093/rheumatology/kep198. Epub 2009 Jul 20.

4

Effective coverage and reimbursement strategies for etanercept and infliximab in the treatment of rheumatoid arthritis.依那西普和英夫利昔单抗治疗类风湿关节炎的有效覆盖范围及报销策略。

Manag Care Interface. 2005 Apr;18(4):32-7.

5

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.模拟包括肿瘤坏死因子阻断剂和来氟米特在内的治疗策略在荷兰治疗类风湿性关节炎的5年成本效益。

Arthritis Rheum. 2004 Dec 15;51(6):964-73. doi: 10.1002/art.20843.

6

Cost-effectiveness analysis: out of touch with clinical reality?

Arthritis Rheum. 2005 Feb 15;53(1):3-4. doi: 10.1002/art.20906.

7

Etanercept or infliximab: the patient's considerations.依那西普或英夫利昔单抗：患者的考量因素。

Arch Intern Med. 2006 Jul 10;166(13):1418; author reply 1418. doi: 10.1001/archinte.166.13.1418-a.

8

Rituximab (Rituxan) for rheumatoid arthritis.利妥昔单抗（美罗华）用于治疗类风湿性关节炎。

Med Lett Drugs Ther. 2006 Apr 24;48(1233):34-5.

9

Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment.英夫利昔单抗治疗前及治疗期间慢性炎性关节病患者的药物经济学研究

Ann Rheum Dis. 2006 Jul;65(7):924-8. doi: 10.1136/ard.2005.041574. Epub 2005 Dec 8.

10

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.利用瑞典南部的登记数据对利妥昔单抗治疗类风湿关节炎的成本效益进行建模。

Int J Technol Assess Health Care. 2009 Apr;25(2):181-9. doi: 10.1017/S0266462309090230. Epub 2009 Mar 31.